Table of Content



1. Introduction To The Report

2. Pre-Eclampsia: Summary

3. Overview
3.1. Introduction
3.2. Pathophysiology Of Pre-Eclampsia
3.2.1. Stage 1
3.2.2. Stage 2
3.2.3. Limitations Of The Placenta Model
3.3. Systemic Manifestations Of Pre-Eclampsia
3.3.1. Central Nervous System (Cns)
3.3.2. Cardiovascular Systems
3.3.3. Liver
3.3.4. Kidney
3.3.5. Other Targets
3.4. Diagnosis
3.5. Management Of Pre-Eclampsia
3.5.1. Antihypertensive Treatment
3.5.2. Magnesium Sulfate
3.5.3. Delivery And Termination Of Pregnancy

4. Market Dynamics
4.1. Key Drivers
4.1.1. Advances In Research And Development
4.1.2. Higher Maternal Age And Associated Health Conditions
4.1.3. Increasing Prevalence Of Pre-Eclampsia
4.2. Key Restraints
4.2.1. Elevated Development Costs
4.2.2. Lack Of Knowledge Of The Underlying Root Causes
4.2.3. Healthcare Access Inequities

5. Pipeline Therapeutics
5.1. Pipeline Scenario

6. Early-Stage Products (Phase I)
6.1. Comparative Analysis
6.2. Cbp-4888: Comanche Biopharma
6.2.1. Product Description
6.2.2. Research And Development
6.2.3. Product And Developmental Activities

7. Unmet Needs



List of Figures

List Of Figures
Figure 1: Contributing Factors And The Two-Stage Models Of Pre-Eclampsia
Figure 2: Systemic Manifestations Of Pre-Eclampsia
Figure 3: Liver Dysfunction (Hellp Syndrome)
Figure 4: Pulmonary Edema
Figure 5: Early-Stage Products (Phase I)

List of Tables

LIST OF TABLES
TABLE 1: CLASSIFICATION OF PRE-ECLAMPSIA ACCORDING TO GESTATIONAL AGE
TABLE 2: TOTAL ACTIVE PRODUCTS IN PRE-ECLAMPSIA PIPELINE
TABLE 3: EARLY-STAGE PRODUCTS (PHASE I)
TABLE 4: CLINICAL TRIALS DESCRIPTION: CBP-4888
TABLE 5: GENERAL DESCRIPTION: CBP-4888